TABLE 1.
Clinical characteristics of 162 patients with high‐risk non‐metastatic prostate cancer in the training and validation cohorts.
| Characteristics | Whole cohort (n = 162) | Training cohort (n = 113) | Validation cohort (n = 49) | p‐value |
|---|---|---|---|---|
| Age (years), mean ± SD | 70.28 ± 6.21 | 69.97 ± 6.62 | 71.02 ± 5.15 | 0.276 |
| BMI (kg/m2), mean ± SD | 23.38 ± 3.69 | 23.62 ± 3.77 | 22.82 ± 3.46 | 0.212 |
| Initial PSA at diagnosis (ng/mL), median (range) | 29.81 (17.24–86.11) | 29.49 (17.24–86.11) | 30.82 (18.39–77.77) | 0.099 |
| ISUP grading group of biopsy specimens, n (%) | ||||
| 3 | 46 (28.40%) | 34 (30.09%) | 12 (24.49%) | 0.721 |
| 4 | 75 (46.30%) | 52 (46.02%) | 23 (46.94%) | |
| 5 | 41 (25.30%) | 27 (23.89%) | 14 (28.57%) | |
| EAU clinical T stage, n (%) | ||||
| 2c | 12 (7.41%) | 10 (8.85%) | 2 (4.08%) | 0.675 |
| 3a | 63 (38.89%) | 45 (39.82%) | 18 (36.73%) | |
| 3b | 76 (46.91%) | 50 (44.25%) | 26 (53.06%) | |
| 4 | 11 (6.79%) | 8 (7.08%) | 3 (6.12%) | |
| PI‐RADS v2 score, n (%) | ||||
| 3 | 16 (9.88%) | 11 (9.73%) | 5 (10.20%) | 0.597 |
| 4 | 79 (48.77%) | 58 (51.33%) | 21 (42.86%) | |
| 5 | 67 (41.36%) | 44 (38.94%) | 23 (46.94%) | |
| Pathological response, n (%) | ||||
| pCR | 16 (9.88%) | 10 (8.85%) | 6 (12.24%) | 0.935 |
| MRD | 47 (29.01%) | 34 (30.09%) | 13 (26.53%) | |
| SRD | 99 (61.11%) | 69 (61.06%) | 30 (61.22%) | |
Abbreviations: BMI, body mass index; EAU, European Association for Urology; ISUP, International Society of Urological Pathology; PI‐RADS v2, Prostate Imaging Reporting and Data System version 2; PSA, prostate‐specific antigen.